HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Capital Markets

Shanghai Pulse Medical Technology / Equity Capital Markets

<ul>
<li>The products of <a href="https://www.smartkarma.com/entities/shanghai-pulse-medical-technology" target="_blank" data-smartkarma-citation="entities:35581:1" rel="noopener">Shanghai Pulse Medical Technology (PMT HK)</a> have entered the commercialization stage, indicating that the Company has gone through the stage from 0 to 1.</li>
<li>The medical insurance coverage and CE Mark offer Pulse more options in terms of commercialization, which is very vital especially in front of domestic policy risk and unfriendly financing environment.</li>
<li>Next, Pulse needs to focus more on how to increase the market penetration, so as to present promising commercialization results. Overall, we are looking forward to the future of Pulse.</li>
</ul>


The products of Shanghai Pulse Medical Technology (PMT HK) have entered the commercialization stage, indicating that the Company has gone through the stage from 0 to 1.
The medical insurance coverage and CE Mark offer Pulse more options in terms of commercialization, which is very vital especially in front of domestic policy risk and unfriendly financing environment.
Next, Pulse needs to focus more on how to increase the market penetration, so as to present promising commercialization results. Overall, we are looking forward to the future of Pulse.


Pre-IPO Shanghai Pulse Medical Technology - The Industry, the Business and the Concerns

<ul>
<li>The combination of FFR and IMR can provide a complete functional evaluation from epicardial arteries to myocardial microcirculation,pushing the precise diagnosis and treatment of coronary disease into a new era.</li>
<li>Rainmed’s caFFR System and caIMR System have obvious technical and first-mover advantages; The CE certificate also opens up the imagination space of product commercialization (such as developing markets).</li>
<li>However, the concerns on current sales model, market acceptance, medical insurance coverage, cash flow pressure and market sentiment when IPO should also not be neglected. </li>
</ul>


The combination of FFR and IMR can provide a complete functional evaluation from epicardial arteries to myocardial microcirculation,pushing the precise diagnosis and treatment of coronary disease into a new era.
Rainmed’s caFFR System and caIMR System have obvious technical and first-mover advantages; The CE certificate also opens up the imagination space of product commercialization (such as developing markets).
However, the concerns on current sales model, market acceptance, medical insurance coverage, cash flow pressure and market sentiment when IPO should also not be neglected. 


Pre-IPO Rainmed Medical - The Industry, the Business and the Concerns

Hong Kong

Research and development, clinical operations, manufacturing, regulatory communication, business development and commercialization of medical devices.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Rainmed Medical (2297 HK)

Pre-IPO Shanghai Pulse Medical Technology - The Industry, the Business and the Concerns

Pulse has commercialized its products, with NRDL coverage in China and CE Marks in overseas. So, it has gone through the stage from 0 to 1. Next,...

Xinyao (Criss) Wang

Pre-IPO Rainmed Medical - The Industry, the Business and the Concerns

Rainmed's core products have obvious advantage. With synergies between products, Rainmed can reshape the diagnosis/treatment process.Concerns are...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)